Weekly online symptom reporting was linked to five months' longer survival in lung cancer

The edition in brief

In SYMPRO-Lung, a stepped-wedge cluster-randomised trial at 14 Dutch hospitals, patients starting treatment for stage I to IV lung cancer completed weekly online symptom reports for a year. A post-hoc analysis of 446 patients over a median 50 months found median survival of 26 months with monitoring against 21 months without (adjusted HR 0.80, 95% CI 0.63 to 1.00); progression-free survival did not differ. A living guideline on salivary adjunct tests for oral cancer recommends them for research only, and restates that every adult should have a clinical oral examination and persistent mucosal lesions should be biopsied or referred. The American Association for Thoracic Surgery has revised its 2023 consensus on early-stage non-small cell lung cancer to reflect trials of perioperative chemoimmunotherapy and adjuvant targeted therapy, and continues to stress molecular testing and multidisciplinary review. A phase 1 trial of the nectin-4 antibody-drug conjugate SHR-A2102 in 395 Chinese patients reported grade 3 to 4 treatment-related adverse events in 54%, mostly cytopenias. A meta-analysis of 15 trials found exercise reduced depressive symptom scores in lung cancer, with very low certainty.